Cargando…
Can novel therapeutics halt the amyloid cascade?
The amyloid hypothesis provides a basis for the development of new therapeutic strategies in Alzheimer's disease. Two large trials have recently been published. The first is a phase 2 study of passive immunotherapy with bapineuzumab, a humanized anti-Aβ monoclonal antibody directed against the...
Autores principales: | Prins, Niels D, Visser, Pieter Jelle, Scheltens, Philip |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876783/ https://www.ncbi.nlm.nih.gov/pubmed/20388189 http://dx.doi.org/10.1186/alzrt28 |
Ejemplares similares
-
Can The March of COVID-19 be Halted
por: Loomba, Poonam, et al.
Publicado: (2020) -
Amyloid imaging in clinical trials
por: Ossenkoppele, Rik, et al.
Publicado: (2013) -
The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design
por: Bertens, Daniela, et al.
Publicado: (2017) -
Amyloid imaging in prodromal Alzheimer's disease
por: Ossenkoppele, Rik, et al.
Publicado: (2011) -
Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population
por: Bertens, Daniela, et al.
Publicado: (2017)